Lycia Therapeutics, Inc. Form S-1/A — Oct 20, 2026
Lycia Therapeutics filed Amendment No. 1 to its S-1 for a 14.7 million-share IPO priced at $16.00 to $18.00 per share, with an underwriters' option for 2.205 million additional shares. The company expects net proceeds of approximately $227.8 million at the $17.00 midpoint, or $262.7 million if the option is exercised in full. Lycia is a clinical-stage biotech developing LYTAC extracellular protein degraders, led by LCA-0061 for IgE-mediated food allergy, which showed a mean maximum IgE reduction of 96% in the first Phase 1 cohort, plus LCA-0321 for Graves' disease.
Key figures
- Net Income
- -$19.2 million for the six months ended June 30, 2026; -$36.5 million for FY2025
- Total Assets
- 156760000
- Cash Position
- approximately $138.2 million as of September 30, 2026 (preliminary); $148.1 million as of June 30, 2026
- Gross Proceeds
- approximately $227.8 million net ($262.7 million if greenshoe exercised in full)
- Offering Price
- $16.00-$18.00 per share ($17.00 midpoint assumed)
- Shares Offered
- 14700000
- Shares Outstanding
- 52,094,559 after the offering (54,299,559 with full greenshoe)
- Cash Runway
- into the second half of 2029 post-offering
- Greenshoe Shares
- 2205000
- Reverse Split Ratio
- 1-for-4.5087
- Accumulated Deficit
- $136.8 million as of June 30, 2026
- Capital Raised Since Inception
- $266.6 million
- Lyca0061 Mean Max Ig EReduction
- 96% from baseline
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.